# Study to Investigate the Pharmacokinetic Profile

> **NCT03286829** · PHASE1 · COMPLETED · sponsor: **Saniona** · enrollment: 60 (actual)

## Conditions studied

- Healthy Male Subjects

## Interventions

- **DRUG:** Tesomet "High dose" in fasted condition
- **DRUG:** Tesomet "Low dose" in fasted condition
- **DRUG:** Comperator 1 mg tesofensine, 25 mg commercial IR metoprolol, 75 mg commercial ER metoprolol, fasted condition.
- **DRUG:** Tesomet "High dose" in fed condition

## Key facts

- **NCT ID:** NCT03286829
- **Lead sponsor:** Saniona
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-18
- **Primary completion:** 2018-02-06
- **Final completion:** 2018-02-06
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03286829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03286829, "Study to Investigate the Pharmacokinetic Profile". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03286829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*